SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells

Biochimie

Volumn 94, Issue 2, 2012, Pages 287-299

  Lauricella, M ^a   Ciraolo, A ^a   Carlisi, D ^a   Vento, R ^a   Tesoriere, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anoikis; BimEL; EGFR; FAK; SAHA; TRAIL

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; FLICE INHIBITORY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ANOIKIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CELL ASSAY; CELL DETACHMENT; CELL VIABILITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR INTERACTION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANOIKIS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL ADHESION; CELL LINE, TUMOR; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84855862321     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2011.06.031     Document Type: Article

References (62)

1. J.R. Pasqualini The selective estrogen enzyme modulators in breast cancer: a review Biochim. Biophys. Acta 1654 2004 123 143 (Pubitemid 38681205)
2. W.R. Miller Biological rationale for endocrine therapy in breast cancer Best. Pract. Res. Clin. Endocrinol. Metab. 18 2004 1 32 (Pubitemid 38324624)
3. A. Morani, M. Warner, and J.A. Gustafsson Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues J. Intern. Med. 264 2008 128 142 (Pubitemid 351962577)
4. Y. Miyoshi, K. Akazawa, S. Kamigaki, S. Ueda, T. Yanagisawa, T. Inoue, J. Yamamura, T. Taguchi, Y. Tamaki, and S. Noguchi Prognostic significance of intra-tumoral estradiol level in breast cancer patients Cancer Lett. 216 2004 115 121 (Pubitemid 39410503)
5. J. Bange, E. Zwick, and A. Ullrich Molecular targets for breast cancer therapy and prevention Nat. Med. 7 2001 548 552 (Pubitemid 32448320)
6. W.J. Gradishar Adjuvant endocrine therapy for early breast cancer: the story so far Cancer Invest. 28 2010 433 442
7. J. Mathew, K.S. Asgeirsson, L.R. Jackson, K.L. Cheung, and J.F.R. Robertson Neoadjuvant endocrine treatment in primary breast cancer - review of literature Breast 18 2009 339 344
8. H. Rochefort, M. Glondu, M.E. Sahla, N. Platet, and M. Garcia How to target estrogen receptor- negative breast cancer? Endocr. Relat. Cancer 10 2003 261 266 (Pubitemid 36758652)
9. R. Koschny, H. Walczak, and T.M. Ganten The promise of TRAIL-potential and risks of a novel anticancer therapy J. Mol. Med. 85 2007 923 935 (Pubitemid 47282789)
10. R.A. Daniels, H. Turley, F.C. Kimberley, X.S. Liu, J. Mongkolsapaya, P. Chen, X.N. Xu, J. Boquan, F. Pezzella, and G.R. Screaton Expression of TRAIL and TRAIL receptors in normal and malignant tissues Cell Res. 15 2005 430 438 (Pubitemid 41642871)
11. S.J. Hotte, H.W. Hirte, E.X. Chen, L.L. Siu, L.H. Le, A. Corey, A. Iacobucci, M. MacLean, L. Lo, N.L. Fox, and A.M. Oza A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies Clin. Cancer Res. 14 2008 3450 3455
12. T.S. Griffith, B. Stokes, T.A. Kucaba, J.K. Earel Jr. , R.L. VanOosten, E.L. Brincks, and L.A. Norian TRAIL gene therapy: from preclinical development to clinical application Curr. Gene Ther. 9 2009 9 19
13. J. Cheng, B.L. Hylander, M.R. Baer, X. Chen, and E.A. Repasky Multiple mechanisms underlie resistance of leucemia cells to Apo2 Ligand/TRAIL Mol. Cancer Ther. 5 2006 1844 1853 (Pubitemid 44323253)
14. D. Carlisi, A. D'Anneo, L. Angileri, M. Lauricella, S. Emanuele, A. Santulli, R. Vento, and G. Tesoriere Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation J. Cell Physiol. 226 2011 1632 1641
15. T.J. Sayers, and W.J. Murphy Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy Cancer Immunol. Immunother 55 2006 76 84 (Pubitemid 41783297)
16. V. Lakshmikanthan, I. Kaddour-Djebbar, R.W. Lewis, and M.V. Kumar SAHA-sensitized prostate cancer cells to TNFa-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis Int. J. Cancer 119 2006 221 228
17. K. Miyashita, K. Shiraki, H. Fuke, T. Inoue, Y. Yamanaka, Y. Yamaguchi, N. Yamamoto, K. Ito, K. Sugimoto, and T. Nakano The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis Int. J. Mol. Med. 18 2006 249 256
18. S. Nakata, T. Yoshida1, M. Horinaka, T. Shiraishi, M. Wakada, and T. Sakai Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells Oncogene 23 2004 6261 6271 (Pubitemid 39215296)
19. S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D'Anneo, P. Di Fazio, R. Vento, and G. Tesoriere SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib Apoptosis 12 2007 1327 1338 (Pubitemid 46890392)
20. D. Carlisi, M. Lauricella, A. D'Anneo, S. Emanuele, L. Angileri, P. Di Fazio, A. Santulli, R. Vento, and G. Tesoriere The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation Eur. J. Cancer 45 2009 2425 2438
21. C. Park, D.O. Moon, C.H. Ryu, B. Choi, W. Lee, G.Y. Kim, and Y. Choi β-Sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis Acta Pharmacol. Sin 29 2008 341 348 (Pubitemid 351316993)
22. T.R. Singh, S. Shankar, and R.K. Srivastava HDAC inhibitors enhance the apoptosis-indicing potential of TRAIL in breast carcinoma Oncogene 24 2005 4609 4623 (Pubitemid 41032599)
23. L.M. Butler, V. Liapis, S. Bouralexis, K. Welldon, S. Hay, L.M. Thai, A. Labrinidis, W.D. Tilley, D.M. Findlay, and A. Evdokiou The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL Int. J. Cancer 119 2006 944 954 (Pubitemid 44051462)
24. P. Chiarugi, and E. Giannoni Anoikis: a necessary death program for anchorage-dependent cells Biochem. Pharmacol. 76 2008 1352 1364
25. M. Giuliano, M. Lauricella, G. Calvaruso, M. Carabill, S. Emanuele, R. Vento, and G. Tesoriere The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells Cancer Res. 59 1999 5586 5595 (Pubitemid 29526478)
26. K. Subik, J.F. Lee, L. Baxter, T. Strzepek, D. Costello, P. Crowley, L. Xing, M.C. Hung, T. Bonfiglio, D.G. Hicks, and P. Tang The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines Breast Cancer 4 2010 35 41
27. B. Sung, B. Park, V.R. Yadav, and B.B. Aggarwal Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors J. Biol. Chem. 285 2010 11498 11507
28. F.G. Giancotti Complexity and specificity of integrin signalling Nat. Cell Biol. 2 2000 E13 E14
29. S.K. Mitra, and D.D. Schlaepfer Integrin-regulated FAK-Src signaling in normal and cancer cells Curr. Opin. Cell Biol. 18 2006 516 523 (Pubitemid 44332916)
30. G. Liu, X. Meng, Y. Jin, J. Bai, Y. Zhao, X. Cui, F. Chen, and S. Fu Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549 Cell. Biol. Int. 32 2008 663 670
31. M. Morini, M. Mottolese, N. Ferrari, F. Ghiorzo, S. Buglioni, R. Mortarini, D.M. Noonan, P.G. Natali, and A. Albini The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity Int. J.Cancer 87 2000 336 342 (Pubitemid 30451643)
32. R.S. Sawhney, W. Liu, and M.G. Brattain A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via FAK signaling Cell. Physiol. 219 2009 152 161
33. K.K. Haenssen, S.A. Caldwell, K.S. Shahriari, S.R. Jackson, K.A. Whelan, A.J. Klein-Szanto, and M.J. Reginato ErbB2 requires integrin α5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells J. Cell Sci. 123 2010 1373 1382
34. V. Golubovskaya, L. Beviglia, L.H. Xu, H.S. Earp, R. Craven, and W. Cance Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor mediated apoptosis in human breast cancer cells J. Biol. Chem. 277 2002 38978 38987 (Pubitemid 35154764)
35. W. Long, P. Yi, L. Amazit, H.L. LaMarca, F. Ashcroft, R. Kumar, M.A. Mancini, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration Mol. Cell 12 2010 321 332
36. K.E. Ewings, C.M. Wiggins, and S.J. Cook Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels Cell Cycle 6 2007 2236 2240 (Pubitemid 47547699)
37. R. Ley, K.E. Ewings, K. Hadfield, and S.J. Cook Regulatory phosphorylation of Bim: sorting out the ERK from the JNK Cell Death Differ. 12 2005 1008 1014 (Pubitemid 41065418)
38. R. Ley, K. Balmanno, K. Hadfield, C. Weston, and S.J. Cook Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim J. Biol. Chem. 278 2003 18811 18816 (Pubitemid 36799262)
39. H. Fukazawa, K. Noguchi, A. Masumi, Y. Murakami, and Y. Uehara BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase inhibitors Mol. Cancer Ther. 3 2004 1281 1288 (Pubitemid 39445336)
40. J. Deng, T. Shimamura, S. Perera, N.E. Carlson, D. Cai, G.I. Shapiro, K.K. Wong, and A. Letai Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion Cancer Res. 67 2007 11867 11875
41. N. Uehara, Y. Matsuoka, and A. Tsubura Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells Mol. Cancer Res. 2008
42. P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.G. Wang, V. Richon, and K. Bhalla Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 Clin. Cancer Res. 11 2005 6382 6389 (Pubitemid 41262970)
43. N.E. Davidson, E.P. Gelmann, M.E. Lippman, and R.B. Dickson Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines Mol. Endocrinol. 1 1987 216 223
44. A. Susan Chrysogelos, and Robert B. Dickson EGF receptor expression, regulation, and function in breast cancer J. Biol. Chem. 275 39 2000 30597 30604
45. H. Harada, B. Quearry, A. Ruiz-Vela, and S.J. Korsmeyer Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity PNAS 26 2004 15313 15317 (Pubitemid 39441538)
46. T. Frogne, R.V. Benjaminsen, K. Sonne-Hansen, B.S. Sorensen, E. Nexo, A.V. Laenkholm, L.M. Rasmussen, D.J. Riese, P. de Cremoux, J. Stenvang, and A.E. Lykkesfeldt Activation of ErbB3, EGFR and ERK is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant Breast Cancer Res. Treat. 114 2009 263 725
47. Y.G. Zhang, Q. Du, W.-G. Fang, M.-L. Jim, and X.-X. Tian Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells Int. J. Oncol. 33 2008 595 602
48. H. Yamagata, S. Shimizu, Y. Nishida, Y. Watanabe, W.J. Craigen, and Y. Tsujimoto Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity of Bax Oncogene 28 2009 3563 3572
49. J.S. Burmeister, J.D. Vrany, W.M. Reichert, and G.A. Truskey Effect of fibronectin amount and conformation on the strength of endothelial cell adhesion to HEMA/EMA copolymers J. Biomed. Mater. Res. 30 1996 13 22 (Pubitemid 26015682)
50. E. Shankar, U. Sivaprasad, and A. Basu Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53 Oncogene 27 2008 3957 3966 (Pubitemid 351913642)
51. B. Pennarun, A. Meijer, E.G. de Vries, J.H. Kleibeuker, F. Kruyt, and S. de Jong Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer Biochim. Biophys. Acta 1805 2010 123 140
52. M.Z. Gilcrease, X. Zhou, X. Lu, W.A. Woodward, B.E. Hall, and P.J. Morrissey Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer J. Exp. Clin. Cancer Res. 28 2009 67 77
53. H. Shimizu, N. Koyama, M. Asada, and K. Yoshimatsu Aberrant expression of integrin and erbB subunits in breast cancer cell lines Int. J. Oncol. 21 2002 1073 1079
54. E.A. Beierle, X. Ma, A. Trujillo, E.V. Kurenova, W.G. Cance, and V.M. Golubovskaya Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines Mol. Carcin 49 2010 224 234
55. S.H. Kim, and S.H. Kim Antagonistic effect of EGF on FAK phosphorylation/dephosphorylation in a cell Cell. Biochem. Funct. 26 2008 539 547
56. Q. Zhou, P.G. Shaw, and N.E. Davidson Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells Breast Cancer Res. Treat. 117 2009 443 451
57. M.J. Reginato, K.R. Mills, J.K. Paulus, D.K. Lynch, D.C. Sgroi, J. Debnath, S.K. Muthuswamy, and J.S. Brugge Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis Nat. Cell Biol. 5 2003 733 740 (Pubitemid 36986781)
58. S. Saleem, J. Li, S.-P. Yee, G.F. Fellows, C.G. Goodyer, and R. Wang β1 integrin/FAK/ERK signalling pathway is essential for human fetal islet cell differentiation and survival J. Pathol. 219 2009 182 192
59. E.H. Cheng, M.C. Wei, S. Weiler, R.A. Flavell, T.W. Mak, T. Lindsten, and S.J. Korsmeyer BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis Mol. Cell 8 2001 705 711 (Pubitemid 32946946)
60. C.D. Simpson, K. Anyiwe, and A.D. Schimmer Anoikis resistance and tumor metastasis Cancer Lett. 272 2008 177 185
61. H. Fukazawa, K. Noguchi, Y. Murakami, and Y. Uehara Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway Mol. Cancer Ther. 1 2002 303 309
62. S. Shankar, R. Davis, K.P. Singh, R. Kurzrock, D.D. Ross, and R.K. Srivastava Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice Mol. Cancer Ther. 8 2009 1596 1605